NCT06786533 - Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Interventions

DRUG

Anti-FLT3 CAR-T cells

Anti-FLT3 CAR-T cells is administered by intravenous infusion following standard lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide.

Trial Locations (1)

77030

RECRUITING

MD Anderson, Houston